Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.

Cancer Causes Control 2017 Jun 27;28(6):557-562. Epub 2017 Mar 27.

Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.

Purpose: Breast cancer patients can switch hormonal therapy (HT) regimens due to treatment side effects or menopausal status change. We describe HT class switching from aromatase inhibitor (AI) to tamoxifen (TAM), and vice versa.

Methods: In a cohort of 3,265 women diagnosed with hormone-receptor-positive breast cancer at Kaiser Permanente Northern California from 2005 to 2013, we analyzed prescription records, switching reasons, and treatment adherence post-switch by chart review, through 31 December 2014.

Results: There were 290 women who switched from AI to TAM (AI switchers), including 130 (45%) switchers during the first year of treatment; and 446 women who switched from TAM to AI (TAM switchers), including 120 (27%) switchers within the first year. After the switch, 136 (47%) AI switchers and 260 (58%) TAM switchers finished or remained on the planned therapy; 69 (24%) AI switchers and 99 (22%) TAM switchers discontinued therapy. AI side effects (73%), specifically joint pain/arthralgia and bone health issues, were the most common reasons for switching from AI to TAM, whereas from TAM to AI, it was menopausal status change (42%).

Conclusions: Study findings highlight the need for better ways to control patient symptoms from HT to prevent discontinuation, and thus ensure best prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-017-0888-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439523PMC
June 2017
4 Reads

Publication Analysis

Top Keywords

tam switchers
16
breast cancer
12
switched tam
8
switchers
8
switchers year
8
tam tam
8
status change
8
menopausal status
8
side effects
8
tam
8
women switched
8
switchers including
8
hormonal therapy
8
reasons switching
8
year switch
4
27% switchers
4
120 27%
4
including 120
4
records switching
4
switch 136
4

References

(Supplied by CrossRef)

CJ Fabian et al.
Int J Clin Pract 2007

HJ Burstein et al.
J Clin Oncol 2010

M Dowsett et al.
J Clin Oncol 2010

M Dowsett et al.
Lancet 2015

DL Hershman et al.
J Clin Oncol 2010

DL Hershman et al.
Breast Cancer Res Treat 2010

RT Chlebowski et al.
Cancer Prev Res 2014

U Guth et al.
Breast Cancer Res Treat 2011

ML Kwan et al.
Cancer Causes Control 2008

JV Selby et al.
2005

W He et al.
J Clin Oncol 2015

Similar Publications